Verastem Oncology
Verastem Oncology is a biopharmaceutical company focused on developing and commercializing medicines to improve the lives of patients with cancer. The company is headquartered in Needham, Massachusetts, United States.
History[edit]
Verastem Oncology was founded in 2010 by a group of scientists and entrepreneurs, including Robert Weinberg, a prominent cancer researcher. The company was established with the goal of developing therapies targeting cancer stem cells, which are believed to be responsible for tumor growth and recurrence.
In 2012, Verastem went public and was listed on the NASDAQ stock exchange under the ticker symbol VSTM. Over the years, the company has focused on developing treatments for various types of cancer, including leukemia, lymphoma, and solid tumors.
Research and Development[edit]
Verastem Oncology's research is centered on targeting cancer stem cells and the tumor microenvironment. The company has developed a pipeline of drug candidates that aim to disrupt the signaling pathways critical for cancer cell survival and proliferation.
One of the company's lead products is duvelisib, an oral dual inhibitor of PI3K-delta and PI3K-gamma, which has been approved for the treatment of certain types of blood cancers. Verastem is also exploring the potential of other compounds in its pipeline for the treatment of solid tumors.
Collaborations and Partnerships[edit]
Verastem Oncology has entered into several strategic collaborations and partnerships to advance its research and development efforts. These partnerships have included collaborations with academic institutions, research organizations, and other pharmaceutical companies to enhance the development of its drug candidates.
Market and Financials[edit]
As a publicly traded company, Verastem Oncology reports its financial performance on a quarterly basis. The company generates revenue primarily through the sale of its approved products and through licensing agreements with other companies.
Related pages[edit]
References[edit]
-
Official company logo
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
